Database : MEDLINE
Search on : thymoma [Words]
References found : 9554 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 956 go to page                         

  1 / 9554 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29523340
[Au] Autor:Rodríguez Prida J; Trapiella Martínez L; Astudillo González A
[Ad] Address:Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario de Cabueñes, Gijón, Asturias, España. Electronic address: xurdeprida@gmail.com.
[Ti] Title:Miositis de células gigantes asociada a miastenia gravis y timoma. Giant cell myositis associated with myasthenia gravis and thymoma.
[So] Source:Med Clin (Barc);, 2018 Mar 06.
[Is] ISSN:1578-8989
[Cp] Country of publication:Spain
[La] Language:eng; spa
[Pt] Publication type:LETTER
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  2 / 9554 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29522809
[Au] Autor:Mineo TC; Tamburrini A; Schillaci O; Ambrogi V
[Ad] Address:Department of Surgery and Experimental Medicine, Multidisciplinary Myasthenia Gravis Unit, Policlinico Tor Vergata University, Rome, Italy. Electronic address: mineo@med.uniroma2.it.
[Ti] Title:Onset and Evolution of Clinically Apparent Myasthenia Gravis after Resection of Non-Myasthenic Thymomas.
[So] Source:Semin Thorac Cardiovasc Surg;, 2018 Mar 06.
[Is] ISSN:1532-9488
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Patients with thymoma and without clinical or electromyographical myasthenic signs may occasionally develop myasthenia several years after thymectomy. Hereby, we investigated the predictors and the evolution of this peculiar disease. METHODS: We performed a retrospective analysis in 104 consecutive patients undergoing thymectomy between 1987 and 2013 for thymoma without clinical nor electromyographic signs of myasthenia gravis. Predictors of post-thymectomy onset of myasthenia gravis were investigated with univariale time-to-disease analysis. Evolution of myasthenia was analyzed with time-to-regression analysis. RESULTS: Eight patients developed late myasthenia gravis after a median period of 33 months from thymectomy. No significant correlation was found for age, gender, Masaoka's stage and World Health Organization histology. Only high preoperative serum acetylcholine-receptor antibodies titer (>0.3 nmol/L) was significantly associated with post-thymectomy myasthenia gravis at univariale time-to-disease (p=0.003) analysis. Positron emission tomography was always performed in high-titer patients detecting activity in 4 of these. Surgical treatment through redo-sternotomy or video-thoracoscopy was performed in these last cases with a remission in all patients after 12, 24, 32 and 48 months, respectively. No patient under medical treatment has yet developed a complete remission. CONCLUSIONS: In our study the presence of pre-operative high-level serum acetylcholine receptor antibodies was the only factor significantly associated with the development of post-thymectomy myasthenia gravis. The persistence of residual islet of ectopic thymic tissue was one of the causes of the onset of myasthenia and surgical removal of these achieved satisfactory results.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher

  3 / 9554 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29515082
[Au] Autor:Onuki T; Ueda S; Otsu S; Yanagihara T; Kawakami N; Yamaoka M; Inagaki M
[Ad] Address:Department of General Thoracic Surgery, Tsuchiura Kyodo General Hospital, Tsuchiura, Ibaraki, Japan.
[Ti] Title:Thymectomy during Myasthenic Crisis under Artificial Respiration.
[So] Source:Ann Thorac Cardiovasc Surg;, 2018 Mar 07.
[Is] ISSN:2186-1005
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:A 34-year-old man was diagnosed with thymoma, which was evaluated preoperatively as stage II or III, with myasthenia gravis (MG). The size of the tumor was 70 × 44 × 80 mm. No invasion to neighboring organs was observed. Prednisolone was prescribed for stabilization of MG. However, a myasthenic crisis (MC) occurred, and intensive care, including emergent endobronchial intubation followed by artificial ventilation, pulse steroid therapy, high-dose intravenous immunoglobulin, and tacrolimus hydrate, was initiated. A chest computed tomography on day 6 revealed tumor reduction to 50 × 30 × 60 mm. An extended total thymectomy by median sternotomy was performed, and artificial ventilation was continued after that. Scheduled artificial ventilation and steroid therapy together can, therefore, enable complete resection of thymoma in patients undergoing treatment for MC. While ventilation helps avert a respiratory failure, the steroid therapy temporarily reduces the tumor size, making resection easier.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.5761/atcs.cr.17-00176

  4 / 9554 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29377988
[Au] Autor:Veronesi G; Dorn P; Dunning J; Cardillo G; Schmid RA; Collins J; Baste JM; Limmer S; Shahin GMM; Egberts JH; Pardolesi A; Meacci E; Stamenkovic S; Casali G; Rueckert JC; Taurchini M; Santelmo N; Melfi F; Toker A
[Ad] Address:Division of Thoracic Surgery, Humanitas Clinical and Research Center, Milan, Italy.
[Ti] Title:Outcomes from the Delphi process of the Thoracic Robotic Curriculum Development Committee.
[So] Source:Eur J Cardiothorac Surg;, 2018 Jan 25.
[Is] ISSN:1873-734X
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:OBJECTIVES: As the adoption of robotic procedures becomes more widespread, additional risk related to the learning curve can be expected. This article reports the results of a Delphi process to define procedures to optimize robotic training of thoracic surgeons and to promote safe performance of established robotic interventions as, for example, lung cancer and thymoma surgery. METHODS: In June 2016, a working panel was spontaneously created by members of the European Society of Thoracic Surgeons (ESTS) and European Association for Cardio-Thoracic Surgery (EACTS) with a specialist interest in robotic thoracic surgery and/or surgical training. An e-consensus-finding exercise using the Delphi methodology was applied requiring 80% agreement to reach consensus on each question. Repeated iterations of anonymous voting continued over 3 rounds. RESULTS: Agreement was reached on many points: a standardized robotic training curriculum for robotic thoracic surgery should be divided into clearly defined sections as a staged learning pathway; the basic robotic curriculum should include a baseline evaluation, an e-learning module, a simulation-based training (including virtual reality simulation, Dry lab and Wet lab) and a robotic theatre (bedside) observation. Advanced robotic training should include e-learning on index procedures (right upper lobe) with video demonstration, access to video library of robotic procedures, simulation training, modular console training to index procedure, transition to full-procedure training with a proctor and final evaluation of the submitted video to certified independent examiners. CONCLUSIONS: Agreement was reached on a large number of questions to optimize and standardize training and education of thoracic surgeons in robotic activity. The production of the content of the learning material is ongoing.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1093/ejcts/ezx466

  5 / 9554 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28449028
[Au] Autor:Moser B; Fadel E; Fabre D; Keshavjee S; de Perrot M; Thomas P; Brioude G; Van Raemdonck D; Viskens S; Lang-Lazdunski L; Bille A; Weder W; Jungraithmayr W; Ruffini E; Guerrera F; Gómez de Antonio D; Liberman M; Novoa N; Scarci M; Janik S; Klepetko W
[Ad] Address:Department of Thoracic Surgery, Medical University Vienna, Vienna, Austria.
[Ti] Title:Surgical therapy of thymic tumours with pleural involvement: an ESTS Thymic Working Group Project.
[So] Source:Eur J Cardiothorac Surg;52(2):346-355, 2017 Aug 01.
[Is] ISSN:1873-734X
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:OBJECTIVES: Surgery for thymic epithelial tumours (TETs) with pleural involvement is infrequently performed. Thus, the value of surgical therapy for primary or recurrent TETs with pleural involvement is not sufficiently defined yet. METHODS: Twelve institutions contributed retrospective data on 152 patients undergoing surgery (1977-2014) on behalf of the ESTS Thymic Working group. Outcome measures included overall (OS), cause-specific (CSS) and disease-free (DFS) survival as well as freedom from recurrence (FFR). RESULTS: In 70.4% of cases, pleural involvement was present at the time of primary intervention, whereas 29.6% had surgery for recurrent disease involving the pleura. Pleural involvement resulted from thymomas (88.8%) and thymic carcinomas (11.2%). Forty extrapleural pneumonectomies (EPPs), 23 total pleurectomies (TPs), and 88 local pleurectomies (LPs) were performed (completeness of resection in 76.8%). OS for the entire patient population at 1, 3, 5 and 10 years was 96.4%, 91.0%, 87.2% and 62.7%, respectively. There was no statistically significant difference regarding FFR and OS for patients with local or advanced disease undergoing EPP, TP or LP. Thymic carcinomas in comparison with thymomas had a negative impact on OS [hazard ratio 6.506, P = 0.002], CSS and FFR. Incomplete resections predicted worse OS [hazard ratio 6.696, P = 0.003]. CONCLUSIONS: Complete resection remains the mainstay of treatment for TETs with pleural involvement. Study populations treated with EPP, TP and LP had similar survival that may be factual as observed, but in the presence of selection bias, we can further conclude from the results that EPP, TP and LP are equally effective procedures. Procedural choice depends upon the extent of tumour distribution. EPPs, TPs and LPs performed within a multimodality setting seem to be efficient procedures for local control of disease, as they yield excellent results regarding OS, DFS, CSS and FFR.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1704
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Process
[do] DOI:10.1093/ejcts/ezx090

  6 / 9554 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29512373
[Au] Autor:Tavakol M; Mahdaviani SA; Ghaemi MR; Vaezi M; Dorudinia A; Jamaati H; Velayati AA
[Ad] Address:Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran AND Department of Allergy and Clinical Immunology, Shahid Bahonar Hospital, Alborz University of Medical Sciences, Karaj, Iran.
[Ti] Title:Good's Syndrome-Association of the Late Onset Combined Immunodeficiency with Thymoma: Review of Literature and Case Report.
[So] Source:Iran J Allergy Asthma Immunol;17(1):85-93, 2018 Feb.
[Is] ISSN:1735-1502
[Cp] Country of publication:Iran
[La] Language:eng
[Ab] Abstract:Good's syndrome, the adult onset hypogammaglobulinemia associated with thymoma has been explained about six decades ago. It generally presents with recurrent infections and several paraneoplastic syndromes including myasthenia gravis, pure red cell aplasia, connective tissue disorders, superior vena cava, Horner's syndrome, lichen planus and inflammatory bowel disease. Lack of B cell, dysfunction of T cell, CD4+ T cell lymphopenia, reversed CD4/CD8+ T cell ratio, autoantibodies against Th17 related cytokines have been respected as the pathogenesis of the immune dysregulation this syndrome. A 57-year-old man was admitted to our hospital with a history of thymectomy due to thymoma (Type A) 6 years ago. He developed weight loss and recurrent persistent diarrhea caused by isospora belli. His chest CT scan revealed bilateral bronchiectasis. His laboratory data showed hypogammaglobulinemia and he was treated by monthly IVIG with the diagnosis of good's syndrome. Nevertheless he referred again with left sided loss of vision because of CMV retinitis and he also developed nail candidiasis. Good's syndrome should be considered in every patient with a history of thymoma and recurrent infection. Immunologic evaluation of these patients including measurement of the serum level of immunoglobulin as well as B cell and T cell subgroups should be performed. Physicians must be aware and think about this entity in patients with adult onset immunodeficiency.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Data-Review

  7 / 9554 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29472706
[Au] Autor:Di Siena S; Campolo F; Gimmelli R; Di Pietro C; Marazziti D; Dolci S; Lenzi A; Nussenzweig A; Pellegrini M
[Ad] Address:Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University, Rome, Italy.
[Ti] Title:Atm reactivation reverses ataxia telangiectasia phenotypes in vivo.
[So] Source:Cell Death Dis;9(3):314, 2018 Feb 22.
[Is] ISSN:2041-4889
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Hereditary deficiencies in DNA damage signaling are invariably associated with cancer predisposition, immunodeficiency, radiation sensitivity, gonadal abnormalities, premature aging, and tissue degeneration. ATM kinase has been established as a central player in DNA double-strand break repair and its deficiency causes ataxia telangiectasia, a rare, multi-system disease with no cure. So ATM represents a highly attractive target for the development of novel types of gene therapy or transplantation strategies. Atm tamoxifen-inducible mouse models were generated to explore whether Atm reconstitution is able to restore Atm function in an Atm-deficient background. Body weight, immunodeficiency, spermatogenesis, and radioresistance were recovered in transgenic mice within 1 month from Atm induction. Notably, life span was doubled after Atm restoration, mice were protected from thymoma and no cerebellar defects were observed. Atm signaling was functional after DNA damage in vivo and in vitro. In summary, we propose a new Atm mouse model to investigate novel therapeutic strategies for ATM activation in ataxia telangiectasia disease.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Data-Review
[do] DOI:10.1038/s41419-018-0357-8

  8 / 9554 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29225302
[Au] Autor:Kaba E; Ozkan B; Erus S; Duman S; Cimenoglu B; Toker A
[Ad] Address:Department of Thoracic Surgery, Istanbul Bilim University Medical Faculty, Istanbul, Turkey.
[Ti] Title:Role of Surgery in the Treatment of Masaoka Stage IVa Thymoma.
[So] Source:Ann Thorac Cardiovasc Surg;24(1):6-12, 2018 Feb 20.
[Is] ISSN:2186-1005
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:PURPOSE: To analyze the role of surgery in patients with Masaoka stage IVa thymoma treated with multimodality therapy. METHODS: Of 191 patients undergoing surgery for thymoma in our department between January 2002 and December 2015, 39 (20.4%) had Masaoka stage IVa. Histopathological tumor type, myasthenic status of the Osserman-Genkins score, Masaoka stage at the first surgery, neoadjuvant treatment, number and type of surgeries, and survival rates were recorded. RESULTS: Thymoma B2 was the most common histopathological tumor type (n = 16, 41%). Twenty-six (66.7%) patients underwent primary surgeries for Masaoka stage IVa thymoma, whereas nine (23.1%) underwent secondary surgeries and four (10.3%) underwent tertiary surgeries for pleural or pericardial recurrences. Median survival was 132 ± 25 (82-181; 95% confidence interval [CI]) months. Overall 3-, 5-, and 10-year survival rates were 93%, 93%, and 56%, respectively. CONCLUSION: Surgical treatment should be considered as a completion modality to oncological therapy and has the potential to provide long-term survival of Masaoka stage IVa in patients with thymoma. The type of surgery should be determined based on the invasiveness of the lesion.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Process
[do] DOI:10.5761/atcs.oa.17-00108

  9 / 9554 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29226320
[Au] Autor:Ma L; Fu Q; Xu B; Zhou H; Gao J; Shao X; Xiong J; Gu Q; Wen S; Li F; Shen L; Chen G; Fang H; Lyu J
[Ad] Address:Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, College of Laboratory Medicine and Life sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
[Ti] Title:Breast cancer-associated mitochondrial DNA haplogroup promotes neoplastic growth via ROS-mediated AKT activation.
[So] Source:Int J Cancer;142(9):1786-1796, 2018 May 01.
[Is] ISSN:1097-0215
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:In the last decade, mitochondrial DNA (mtDNA) haplogroups have been associated with the occurrence of breast cancer. However, the underlying mechanism is not known. Combining a case-control study with a large cohort of women from Southern China with breast cancer and functional analyses with trans-mitochondrial technology, we demonstrate that the D5 haplogroup is associated with an increased risk of breast cancer [odds ratio (OR) = 2.789; 95% confidence interval (CI) [1.318, 5.901]; p = 0.007]. Furthermore, mitochondrial respiration, mitochondrial ATP content and membrane potential, were lower in both bone osteosarcoma and breast cancer cell models of cytoplasmic hybrids (cybrids) containing the mtDNA D5 haplogroup than in those with non-D5 haplogroups. Using in vitro and in vivo tumorigenicity assays, we found that cells with the D5 haplogroup were more susceptible to tumorigenesis compared to cells with non-D5 haplogroups. Mechanistically, the D5 haplogroup may promote tumorigenesis at least partially through activation of the v-AKT murine thymoma viral oncogene (AKT) via phosphorylation of threonine 308, which is mediated by increased reactive oxygen species generation in D5 cybrids. Our findings demonstrate that there is decreased mitochondrial function in cells with the D5 haplogroup compared to cells with non-D5 haplogroups, which may be associated with increased neoplastic growth in breast cancer.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[St] Status:In-Data-Review
[do] DOI:10.1002/ijc.31207

  10 / 9554 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 28460459
[Au] Autor:Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okon K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
[Ad] Address:Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA.
[Ti] Title:Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
[So] Source:Oncotarget;8(16):26744-26754, 2017 Apr 18.
[Is] ISSN:1949-2553
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Mesothelin (MSLN) is a glycophosphatidylinositol (GPI)-linked cell surface protein highly expressed in several types of malignant tumors sometimes in association with increased tumor aggressiveness and poor clinical outcome. In the present study, 1562 tumors were immunohistochemically analyzed for mesothelin expression using two different types of mouse monoclonal antibodies (5B2 and MN-1) to determine the clinical usefulness of mesothelin immunohistochemistry as well as to pinpoint potential targets for future anti-mesothelin therapy. Also, characterization of selected mesothelin-positive tumors was performed by immunohistochemistry and oncogene sequencing. Among the tumors analyzed, the highest frequencies of mesothelin-positivity were detected in ovarian serous carcinoma (90% in 5B2 and 94% in MN-1). Both antibodies showed frequent positivity in pancreatic adenocarcinoma (71% using 5B2 and 87% using MN-1) and malignant pleural mesothelioma (75% using 5B2 and 78% using MN-1). In malignant mesothelioma, overall survival was significantly longer in the cohort of patients with diffuse membranous expression of mesothelin (P < 0.001). Both antibodies showed positive staining in thymic carcinoma (77% in 5B2 and 59% in MN-1), however, no expression was detected in thymoma. No correlation was detected between mesothelin expression and mismatch repair system deficient phenotype or gene mutation (BRAF and RAS) status in gastrointestinal adenocarcinomas. Mesothelin immunohistochemistry may assist the differential diagnosis of thymoma vs. thymic carcinoma as well as prognostication of mesothelioma patients. Our results demonstrate that patients with solid tumors expressing mesothelin could be targeted by anti-mesothelin therapies.
[Mh] MeSH terms primary: Biomarkers, Tumor
GPI-Linked Proteins/metabolism
Lung Neoplasms/metabolism
Lung Neoplasms/mortality
Mesothelioma/metabolism
Mesothelioma/mortality
Pleural Neoplasms/metabolism
Pleural Neoplasms/mortality
[Mh] MeSH terms secundary: Antibodies, Monoclonal
Diagnosis, Differential
Gene Expression
Humans
Immunohistochemistry
Lung Neoplasms/diagnosis
Lung Neoplasms/genetics
Mesothelioma/diagnosis
Mesothelioma/genetics
Mutation
Pleural Neoplasms/diagnosis
Pleural Neoplasms/genetics
Prognosis
Survival Analysis
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antibodies, Monoclonal); 0 (Biomarkers, Tumor); 0 (GPI-Linked Proteins); 0 (mesothelin)
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[Js] Journal subset:IM
[Da] Date of entry for processing:170503
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.15814


page 1 of 956 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information